macular amyloidosis. Other amyloidosis
Conditions
Interventions
Intervention 1: Intervention group: One side of the lesion (left or right) on the back of each patient is randomly allocated to receive topical Gabapentin in gel based with 0.06 concentration (Temad a
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Clinical diagnosis of macular amyloidosis Age range from 18 to 50 years Corneal skin lesion in the back No history of treatment in the past 6 months Consent to attend to this study No history of gabapentin allergy No interference with other patient medications
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Inability to take medication Renal failure Depression Neurological diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Itching severity. Timepoint: Before intervention and 2, 4 , 6 weeks after intervention with topical Gabapentin. Method of measurement: 12- item severity pruritus scale and 4- item itching questioner.;Pigmentation rate. Timepoint: Before intervention and 2, 4 , 6 weeks after intervention with Gabapentin. Method of measurement: Photo finder system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction. Timepoint: Six month after treatment. Method of measurement: patient satisfaction Visual Analogue Scale score.;Topical side effects of drug use. Timepoint: Four, 8, 12 weeks and 6 months after intervention. Method of measurement: Clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Bahar Saffar
Esfahan University of Medical Sciences
Outcome results
None listed